23 July 1999
Consolidation in the UK pharmaceutical industry has forced the top three companies to review their property strategies, putting new emphasis on flexibility. Lucy Benyon looks at the challenges posed to the traditional property world by this industry
You must be logged in to continue
Register for free to finish this article
Registration includes the following benefits:
To access this article REGISTER NOW
Four articles not enough? SUBSCRIBE for unlimited access to over 100 weekly articles and our comprehensive archive. For as little as £5 per week.